Murphy Nicole 4

What Happened

• Nicole Murphy, Head of Pharmaceutical Operations and Technology at Biogen (BIIB), made two transactions: an open-market purchase of 3 shares on Feb 12, 2026, and a grant of 10,560 restricted stock units (RSUs) on Feb 13, 2026.
• Purchase: 3 shares at $195.03 per share for a reported total of $585. Grant: 10,560 RSUs reported at $0 (derivative award) — the RSUs represent future shares that will vest over time.
• The purchase is a small open-market buy (minor bullish signal given size); the RSU grant is a compensatory award.

Key Details

• Transaction dates and prices:
  • 2026-02-12: Open-market purchase (P) — 3 shares @ $195.03 (reported total $585).
  • 2026-02-13: Award/grant (A) — 10,560 RSUs @ $0.00 (derivative award).
• Vesting: Footnote states the RSUs vest in three equal yearly installments beginning on the first anniversary of the grant date (Feb 13, 2026) — i.e., first vesting on Feb 13, 2027, then annually thereafter.
• Shares owned after transaction: Not disclosed in this Form 4.
• Timeliness: Form filed on 2026-02-17 reporting transactions on 2026-02-12 and 2026-02-13; this filing appears later than the typical 2-business-day Form 4 deadline.
• Transaction codes: P = purchase (open market); A = award/grant (derivative RSU grant).

Context

• The RSU grant is a compensatory award that will convert to common shares as it vests; it carries no immediate purchase price (reported at $0) but has future value tied to BIIB stock price at vesting.
• The 3-share open-market purchase is very small in dollar terms and may be routine; small purchases can still be of interest but are not definitive signals of insider sentiment.
• No indication in this filing of immediate sale of award shares, tax withholding, 10b5-1 plan, or other special conditions beyond the stated vesting schedule.